Overview
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side-effect with severe impact on patients’ quality of life. Despite recently updated antiemesis guidelines, CINV control is suboptimal, with poor patient adherence rates affecting overall outcomes. In this e-learning module, we discuss the importance of CINV management considering risk factors and antiemetic potential of chemotherapy agents. Latest evidence on the potential of dual-pathway targeted therapies will be discussed, along with strategies to overcome specific barriers to treatment.